Abstract
Introduction: A better understanding of patient characteristics and clinical factors contributing to discontinuation of biologics among psoriasis (PSO) patients is necessary to identify opportunities to improve treatment approaches. This study describes comorbidities, comedications, and discontinuation in PSO patients newly initiating biologics in the real-world, including gender differences.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
